Ascensia Diabetes Care and Glooko, a remote patient monitoring platform for diabetes has announced an integration partnership to improve diabetes data management and analytics. The integration includes Glooko’s Diabetes Data Management Platform and Ascensia’s blood glucose monitoring systems that will allow people with diabetes and health care professionals to access and analyze highly accurate blood glucose data through the digital platform of their choice. The collaboration includes all markets where Glooko and these Ascensia systems are available.
“Glooko’s Diabetes Data Management Platform has become widely used for both personal and clinical diabetes data analytics and decision support,” said Michael Kloss, CEO of Ascensia Diabetes Care in a statement. “Glooko’s broad distribution into health systems will enable us to easily and seamlessly deliver highly accurate data from our CONTOUR NEXT®ONE and CONTOUR®PLUS ONE blood glucose monitoring systems to clinicians right in their workflow. By linking our systems to Glooko’s Diabetes Data Management Platform, we want to enable better understanding and analysis of diabetes data, and ultimately help to improve the lives of people with diabetes.”
The integration will allow blood glucose data to be accessed by Glooko’s Mobile App and Clinic Data Upload products directly from the CONTOUR®NEXT ONE and CONTOUR®PLUS ONE meters via Bluetooth® connectivity and through an automatic feed via the CONTOUR CLOUD. People with diabetes will be able to view their data both in Glooko’s Mobile and Web Apps, as well as in the CONTOUR[TM] DIABETES App from Ascensia. Health care professionals will be able to seamlessly access data from these two Ascensia systems in a way that fits directly into their workflow via the Glooko Clinic Solution.
The CONTOUR®NEXT ONE system recently received 510(k) clearance from the FDA and Ascensia Diabetes Care expects to make this system available in the United States in early 2017. n a clinical study, 95% of blood glucose results obtained with CONTOUR®NEXT ONE were within 8.4 mg/dL (0.5 mmol/L) or 8.4% of the reference result for subject fingertip tests. In a similar clinical study, 95% of blood glucose results for CONTOUR®PLUS ONE were within 8.5 mg/dL (0.5 mmol/L) or 8.5% of the reference result for subject fingertip tests.
The integration is expected to be available for people with diabetes and health care professionals later in 2017.